Mindwalk Holdings Corp (HYFT)

$1.16 -0.06 (-4.92%)
Market Cap 53.54M
Revenue (ttm) 17.59M
Net Income (ttm) -21.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -123.31%
Debt to Equity Ratio 0.00
Volume 110,200
Avg Vol 544,508
Day's Range N/A - N/A
Shares Out 46.16M
Stochastic %K 11%
Beta 0.58
Analysts Sell
Price Target $4.00

Company Profile

MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed it...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 620 4187
Address:
Industrious 823 Congress Ave, Suite 300, Austin, United States
Jooner420
Jooner420 Mar. 21 at 1:31 PM
$HYFT
0 · Reply
Flarelords
Flarelords Mar. 21 at 1:31 AM
$HYFT
0 · Reply
RamseysThoughts
RamseysThoughts Mar. 20 at 1:31 PM
$HYFT
0 · Reply
NyseDayTrader
NyseDayTrader Mar. 20 at 11:15 AM
$HYFT imagine being this disconnected from your executive team and watch them continue to buy shares and just ignore the fact . @ Jenn Bath! Time for change……
1 · Reply
BaridBanger
BaridBanger Mar. 20 at 9:41 AM
$HYFT
0 · Reply
NyseDayTrader
NyseDayTrader Mar. 20 at 12:04 AM
$HYFT and another….
0 · Reply
Flarelords
Flarelords Mar. 19 at 10:37 PM
$HYFT signed its first recurring platform contract with its largest enterprise AI client. Shift from project-based to monthly-recognized SaaS-style revenue. Small in scale today but the model change is structurally significant if replicated
1 · Reply
EKingsler
EKingsler Mar. 19 at 10:03 PM
$HYFT see $HYFT evolving from a services company into a platform plus pipeline story
0 · Reply
Lonestardom
Lonestardom Mar. 19 at 9:40 PM
$HYFT The GLP-1 angle is interesting too. With drugs like semaglutide already doing massive numbers, even showing comparable receptor activity in early testing puts $HYFT into a very large and proven market
0 · Reply
Holmes99
Holmes99 Mar. 19 at 9:01 PM
$HYFT just printed its third straight quarter of YoY growth and that consistency matters more than people think.
0 · Reply
Latest News on HYFT
MindWalk Holdings Corp. (HYFT) Q3 2026 Earnings Call Transcript

Mar 12, 2026, 12:42 PM EDT - 9 days ago

MindWalk Holdings Corp. (HYFT) Q3 2026 Earnings Call Transcript

MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

Mar 12, 2026, 8:31 AM EDT - 9 days ago

MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

Mar 6, 2026, 4:01 PM EST - 15 days ago

MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026

Mar 2, 2026, 8:31 AM EST - 19 days ago

MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026

MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics

Jan 27, 2026, 12:01 AM EST - 7 weeks ago

MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

Jan 14, 2026, 8:00 AM EST - 2 months ago

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

Jan 12, 2026, 7:00 AM EST - 2 months ago

REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

Jan 9, 2026, 8:01 PM EST - 2 months ago

MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call Transcript

Dec 15, 2025, 1:29 PM EST - 3 months ago

MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call Transcript

MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline

Dec 15, 2025, 8:30 AM EST - 3 months ago

MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025

Dec 8, 2025, 8:30 AM EST - 3 months ago

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025

MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

Nov 13, 2025, 9:00 AM EST - 4 months ago

MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

Oct 21, 2025, 8:28 AM EDT - 5 months ago

MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

MindWalk Holdings: Repositioned TechBio Platform With Early LensAI Proof Points

Oct 17, 2025, 8:18 AM EDT - 5 months ago

MindWalk Holdings: Repositioned TechBio Platform With Early LensAI Proof Points

MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

Oct 15, 2025, 7:00 AM EDT - 5 months ago

MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

MindWalk Holdings Corp. (HYFT) ImmunoPrecise Antibodies Ltd. - Shareholder/Analyst Call Prepared Remarks Transcript

Oct 9, 2025, 2:26 PM EDT - 5 months ago

MindWalk Holdings Corp. (HYFT) ImmunoPrecise Antibodies Ltd. - Shareholder/Analyst Call Prepared Remarks Transcript

MindWalk Announces Share Repurchase Program

Oct 9, 2025, 7:00 AM EDT - 5 months ago

MindWalk Announces Share Repurchase Program

MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity

Sep 22, 2025, 7:02 AM EDT - 6 months ago

MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity

MindWalk Holdings Corp. (HYFT) Q1 2026 Earnings Call Transcript

Sep 15, 2025, 12:58 PM EDT - 6 months ago

MindWalk Holdings Corp. (HYFT) Q1 2026 Earnings Call Transcript

MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet

Sep 15, 2025, 8:44 AM EDT - 6 months ago

MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet

ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”

Sep 3, 2025, 8:48 AM EDT - 7 months ago

ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York

Sep 2, 2025, 8:01 AM EDT - 7 months ago

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

Aug 27, 2025, 8:22 AM EDT - 7 months ago

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

Aug 6, 2025, 8:00 AM EDT - 8 months ago

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

Aug 6, 2025, 8:00 AM EDT - 8 months ago

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript

Jul 29, 2025, 12:39 PM EDT - 8 months ago

ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

Jul 29, 2025, 8:28 AM EDT - 8 months ago

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

Jul 24, 2025, 8:22 AM EDT - 8 months ago

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

Jul 21, 2025, 8:28 AM EDT - 8 months ago

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

Jul 16, 2025, 8:05 AM EDT - 8 months ago

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 14, 2025, 8:01 AM EDT - 8 months ago

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

Jul 7, 2025, 9:00 AM EDT - 9 months ago

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

Jul 3, 2025, 8:19 AM EDT - 9 months ago

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

Jun 24, 2025, 7:02 AM EDT - 9 months ago

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

Jun 12, 2025, 8:01 AM EDT - 10 months ago

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

Jun 5, 2025, 8:01 AM EDT - 10 months ago

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

AMD

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

May 21, 2025, 8:49 AM EDT - 10 months ago

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

May 20, 2025, 8:28 AM EDT - 10 months ago

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

May 12, 2025, 8:01 AM EDT - 11 months ago

IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

AMD

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

Apr 11, 2025, 8:40 AM EDT - 1 year ago

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript

Mar 28, 2025, 12:59 PM EDT - 1 year ago

ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

Mar 28, 2025, 8:01 AM EDT - 1 year ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

Mar 13, 2025, 7:02 AM EDT - 1 year ago

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

Mar 11, 2025, 10:17 PM EDT - 1 year ago

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

Mar 5, 2025, 8:01 AM EST - 1 year ago

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

Feb 26, 2025, 8:01 AM EST - 1 year ago

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

ImmunoPrecise Antibodies Announces Key Leadership Changes

Feb 24, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies Announces Key Leadership Changes

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

Feb 20, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture

Jan 27, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

Jan 22, 2025, 7:02 AM EST - 1 year ago

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

Jooner420
Jooner420 Mar. 21 at 1:31 PM
$HYFT
0 · Reply
Flarelords
Flarelords Mar. 21 at 1:31 AM
$HYFT
0 · Reply
RamseysThoughts
RamseysThoughts Mar. 20 at 1:31 PM
$HYFT
0 · Reply
NyseDayTrader
NyseDayTrader Mar. 20 at 11:15 AM
$HYFT imagine being this disconnected from your executive team and watch them continue to buy shares and just ignore the fact . @ Jenn Bath! Time for change……
1 · Reply
BaridBanger
BaridBanger Mar. 20 at 9:41 AM
$HYFT
0 · Reply
NyseDayTrader
NyseDayTrader Mar. 20 at 12:04 AM
$HYFT and another….
0 · Reply
Flarelords
Flarelords Mar. 19 at 10:37 PM
$HYFT signed its first recurring platform contract with its largest enterprise AI client. Shift from project-based to monthly-recognized SaaS-style revenue. Small in scale today but the model change is structurally significant if replicated
1 · Reply
EKingsler
EKingsler Mar. 19 at 10:03 PM
$HYFT see $HYFT evolving from a services company into a platform plus pipeline story
0 · Reply
Lonestardom
Lonestardom Mar. 19 at 9:40 PM
$HYFT The GLP-1 angle is interesting too. With drugs like semaglutide already doing massive numbers, even showing comparable receptor activity in early testing puts $HYFT into a very large and proven market
0 · Reply
Holmes99
Holmes99 Mar. 19 at 9:01 PM
$HYFT just printed its third straight quarter of YoY growth and that consistency matters more than people think.
0 · Reply
CanslerPro
CanslerPro Mar. 19 at 8:45 PM
$HYFT Needs time they keep growing
0 · Reply
BenGang
BenGang Mar. 19 at 8:01 PM
$ONDS $REI $HYFT
0 · Reply
NyseDayTrader
NyseDayTrader Mar. 19 at 8:00 PM
$HYFT Its time for Jennifer Bath to step up and buy $100K of shares. We pay this woman a ridiculous amount of money over her worth
0 · Reply
kozyman87
kozyman87 Mar. 19 at 7:02 PM
$HYFT Insider Buying alert 🚨 this is the 3rd time the chief Technology Officer, Dr Dirk Van Hyft and his partner / founder are buying shares Something has them excited 📈‼️
0 · Reply
iambaron
iambaron Mar. 19 at 3:51 PM
$HYFT don’t worry, I’m sure we have a PR planned for tomorrow AH 🥴
2 · Reply
KhanAcademylol
KhanAcademylol Mar. 19 at 1:31 PM
$HYFT
0 · Reply
Twills08
Twills08 Mar. 19 at 4:16 AM
$HYFT 🤔More insider buys… don’t have to tell me twice…
1 · Reply
MexicoCity
MexicoCity Mar. 19 at 1:31 AM
$HYFT
0 · Reply
NyseDayTrader
NyseDayTrader Mar. 19 at 1:22 AM
$HYFT more buying
1 · Reply
MexicanGerman
MexicanGerman Mar. 18 at 7:33 PM
$HYFT let me youst place the focus into the right direction here: there are plenty of AI drug discovery firms. The point is, the focus of AI is sometimes wrong, because what you see are models generating answers. But the models are only the engine. The real fuel is the data to train the models. And here comes the USP of Mindwalk that get overseen. The real value is their database and the way they connect the data ...
0 · Reply
Scam_Likely
Scam_Likely Mar. 18 at 7:11 PM
$HYFT I guess we are going to test $1 again.. of all of the companies - this one is the last affected by this stupid war and raging gas prices.. this is a consumer based company.
1 · Reply
Dominik168
Dominik168 Mar. 18 at 2:14 PM
$HYFT How do you understand this part form ER call : In vivo immunization studies complete; binding confirmation — confirming that immunized animals generated antibodies specifically targeting the conserved cross-serotype epitope — results anticipated this week I was expecting some PR and nothing so far
1 · Reply